-
1
-
-
84883620467
-
Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral T-cell lymphoma
-
Reimer P, Chawla S. Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral T-cell lymphoma. J Hematol Oncol. 2013;6:69.
-
(2013)
J Hematol Oncol
, vol.6
, pp. 69
-
-
Reimer, P.1
Chawla, S.2
-
2
-
-
79959503595
-
Peripheral T-cell lymphoma
-
Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood. 2011;117(25):6756-6767.
-
(2011)
Blood
, vol.117
, Issue.25
, pp. 6756-6767
-
-
Foss, F.M.1
Zinzani, P.L.2
Vose, J.M.3
Gascoyne, R.D.4
Rosen, S.T.5
Tobinai, K.6
-
3
-
-
84892844240
-
Management of relapses after hematopoietic cell transplantation in T-cell non-Hodgkin lymphomas
-
Hamadani M, Abu Kar SM, Usmani SZ, Savani BN, Ayala E, Kharfan-Dabaja MA. Management of relapses after hematopoietic cell transplantation in T-cell non-Hodgkin lymphomas. Semin Hematol. 2014;51(1):73-86.
-
(2014)
Semin Hematol
, vol.51
, Issue.1
, pp. 73-86
-
-
Hamadani, M.1
Abu Kar, S.M.2
Usmani, S.Z.3
Savani, B.N.4
Ayala, E.5
Kharfan-Dabaja, M.A.6
-
4
-
-
84892864994
-
Management of T-cell lymphomas: Overcoming challenges and choosing the best treatment
-
Reddy NM, Savani BN. Management of T-cell lymphomas: overcoming challenges and choosing the best treatment. Semin Hematol. 2014;51(1):1-4.
-
(2014)
Semin Hematol
, vol.51
, Issue.1
, pp. 1-4
-
-
Reddy, N.M.1
Savani, B.N.2
-
5
-
-
84892854428
-
Chemotherapeutic advancements in peripheral T-cell lymphoma
-
Reddy NM, Evens AM. Chemotherapeutic advancements in peripheral T-cell lymphoma. Semin Hematol. 2014;51(1):17-24.
-
(2014)
Semin Hematol
, vol.51
, Issue.1
, pp. 17-24
-
-
Reddy, N.M.1
Evens, A.M.2
-
6
-
-
84892855294
-
Allogeneic transplantation in T-cell lymphomas
-
Schmitz N, Wu HS, Glass B. Allogeneic transplantation in T-cell lymphomas. Semin Hematol. 2014;51(1):67-72.
-
(2014)
Semin Hematol
, vol.51
, Issue.1
, pp. 67-72
-
-
Schmitz, N.1
Wu, H.S.2
Glass, B.3
-
7
-
-
84892838269
-
Autologous stem cell transplantation for T-cell lymphomas
-
Giulia P, Corradini P. Autologous stem cell transplantation for T-cell lymphomas. Semin Hematol. 2014;51(1):59-66.
-
(2014)
Semin Hematol
, vol.51
, Issue.1
, pp. 59-66
-
-
Giulia, P.1
Corradini, P.2
-
8
-
-
84908319588
-
Intensified chemoimmunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma
-
Corradini P, Vitolo U, Rambaldi A, et al. Intensified chemoimmunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia. 2014;28(9):1885-1891.
-
(2014)
Leukemia
, vol.28
, Issue.9
, pp. 1885-1891
-
-
Corradini, P.1
Vitolo, U.2
Rambaldi, A.3
-
9
-
-
0028791591
-
Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells
-
Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer. 1995;76(11):2351-2356.
-
(1995)
Cancer
, vol.76
, Issue.11
, pp. 2351-2356
-
-
Yamaguchi, M.1
Kita, K.2
Miwa, H.3
-
10
-
-
0036176510
-
Mechanisms of cancer drug resistance
-
Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615-627.
-
(2002)
Annu Rev Med
, vol.53
, pp. 615-627
-
-
Gottesman, M.M.1
-
11
-
-
84892945819
-
The changing landscape of peripheral T-cell lymphoma in the era of novel therapies
-
Karlin L, Coiff ier B. The changing landscape of peripheral T-cell lymphoma in the era of novel therapies. Semin Hematol. 2014;51(1):25-34.
-
(2014)
Semin Hematol
, vol.51
, Issue.1
, pp. 25-34
-
-
Karlin, L.1
Coiff Ier, B.2
-
12
-
-
65349137584
-
Histone deacetylase 1, 2, 6 and acetylated histone H4 in B-and T-cell lymphomas
-
Marquard L, Poulsen CB, Gjerdrum LM, et al. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B-and T-cell lymphomas. Histopathology. 2009;54(6):688-698.
-
(2009)
Histopathology
, vol.54
, Issue.6
, pp. 688-698
-
-
Marquard, L.1
Poulsen, C.B.2
Gjerdrum, L.M.3
-
13
-
-
50049108874
-
Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma
-
Marquard L, Gjerdrum LM, Christensen IJ, Jensen PB, Sehested M, Ralfkiaer E. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology. 2008;53(3):267-277.
-
(2008)
Histopathology
, vol.53
, Issue.3
, pp. 267-277
-
-
Marquard, L.1
Gjerdrum, L.M.2
Christensen, I.J.3
Jensen, P.B.4
Sehested, M.5
Ralfkiaer, E.6
-
14
-
-
81555228390
-
Belinostat: Clinical applications in solid tumors and lymphoma
-
Molife LR, de Bono JS. Belinostat: clinical applications in solid tumors and lymphoma. Expert Opin Investig Drugs. 2011;20(12):1723-1732.
-
(2011)
Expert Opin Investig Drugs
, vol.20
, Issue.12
, pp. 1723-1732
-
-
Molife, L.R.1
De Bono, J.S.2
-
15
-
-
34248631385
-
The role of histone deacetylases (HDACs) in human cancer
-
Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 2007;1(1):19-25.
-
(2007)
Mol Oncol
, vol.1
, Issue.1
, pp. 19-25
-
-
Ropero, S.1
Esteller, M.2
-
16
-
-
34547864236
-
Histone deacetylase inhibitors: Molecular mechanisms of action
-
Xu WS, Par migiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007;26(37):5541-5552.
-
(2007)
Oncogene
, vol.26
, Issue.37
, pp. 5541-5552
-
-
Xu, W.S.1
Par Migiani, R.B.2
Marks, P.A.3
-
17
-
-
79952977561
-
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
-
Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117(22):5827-5834.
-
(2011)
Blood
, vol.117
, Issue.22
, pp. 5827-5834
-
-
Piekarz, R.L.1
Frye, R.2
Prince, H.M.3
-
18
-
-
34547683194
-
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
-
Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(21):3109-3115.
-
(2007)
J Clin Oncol
, vol.25
, Issue.21
, pp. 3109-3115
-
-
Olsen, E.A.1
Kim, Y.H.2
Kuzel, T.M.3
-
19
-
-
84872107995
-
Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial
-
Duvic M, Dummer R, Becker JC, et al. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer. 2013;49(2):386-394.
-
(2013)
Eur J Cancer
, vol.49
, Issue.2
, pp. 386-394
-
-
Duvic, M.1
Dummer, R.2
Becker, J.C.3
-
20
-
-
34547122494
-
HDAC inhibitors: Clinical update and mechanism-based potential
-
Glaser KB. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol. 2007;74(5):659-671.
-
(2007)
Biochem Pharmacol
, vol.74
, Issue.5
, pp. 659-671
-
-
Glaser, K.B.1
-
21
-
-
84908275043
-
-
BELEODAQ™ (belinostat) for injection [prescribing information], Inc
-
BELEODAQ™ (belinostat) for injection [prescribing information]. Henderson, NV: Spectrum Pharmaceuticals, Inc.; 2014.
-
(2014)
Henderson, NV: Spectrum Pharmaceuticals
-
-
-
22
-
-
84869869682
-
HDAC inhibitor-based therapies: Can we interpret the code?
-
New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol. 2012;6(6):637-656.
-
(2012)
Mol Oncol
, vol.6
, Issue.6
, pp. 637-656
-
-
New, M.1
Olzscha, H.2
La Thangue, N.B.3
-
23
-
-
78650848615
-
Histone deacetylase inhibitors in the treatment of lymphoma
-
Lemoine M, Younes A. Histone deacetylase inhibitors in the treatment of lymphoma. Discov Med. 2010;10(54):462-470.
-
(2010)
Discov Med
, vol.10
, Issue.54
, pp. 462-470
-
-
Lemoine, M.1
Younes, A.2
-
24
-
-
13344281000
-
Monoclonal antibodies in the treatment of indolent lymphomas
-
Coiffier B. Monoclonal antibodies in the treatment of indolent lymphomas. Best Pract Res Clin Haematol. 2005;18(1):69-80.
-
(2005)
Best Pract Res Clin Haematol
, vol.18
, Issue.1
, pp. 69-80
-
-
Coiffier, B.1
-
25
-
-
33845996135
-
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)
-
Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109(1):31-39.
-
(2007)
Blood
, vol.109
, Issue.1
, pp. 31-39
-
-
Duvic, M.1
Talpur, R.2
Ni, X.3
-
26
-
-
51649126841
-
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma
-
Ellis L, Pan Y, Smyth GK, et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res. 2008;14(14):4500-4510.
-
(2008)
Clin Cancer Res
, vol.14
, Issue.14
, pp. 4500-4510
-
-
Ellis, L.1
Pan, Y.2
Smyth, G.K.3
-
27
-
-
77954504404
-
Final results of a Phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma [abstract]
-
Pohlman B, Advani R, Duvic M, et al. Final results of a Phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma [abstract]. Blood. 2009;114(22):S379.
-
(2009)
Blood
, vol.114
, Issue.22
, pp. S379
-
-
Pohlman, B.1
Advani, R.2
Duvic, M.3
-
28
-
-
84884558230
-
Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial
-
(Suppl; absract 8507)
-
O’Connor OA, Masszi T, Savage KJ, et al. Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): results from the BELIEF trial. J Clin Oncol. 2013;31(Suppl; absract 8507).
-
(2013)
J Clin Oncol
, vol.31
-
-
O’connor, O.A.1
Masszi, T.2
Savage, K.J.3
-
29
-
-
67649595236
-
Belinostat: A new broad acting antineoplastic histone deacetylase inhibitor
-
Gimsing P. Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor. Expert Opin Investig Drugs. 2009;18(4):501-508.
-
(2009)
Expert Opin Investig Drugs
, vol.18
, Issue.4
, pp. 501-508
-
-
Gimsing, P.1
-
30
-
-
38949146399
-
A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors
-
Steele NL, Plumb JA, Vidal L, et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res. 2008;14(3):804-810.
-
(2008)
Clin Cancer Res
, vol.14
, Issue.3
, pp. 804-810
-
-
Steele, N.L.1
Plumb, J.A.2
Vidal, L.3
-
31
-
-
49349104503
-
A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia
-
Gimsing P, Hansen M, Knudsen LM, et al. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol. 2008;81(3):170-176.
-
(2008)
Eur J Haematol
, vol.81
, Issue.3
, pp. 170-176
-
-
Gimsing, P.1
Hansen, M.2
Knudsen, L.M.3
-
32
-
-
79959611523
-
Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)
-
Steele NL, Plumb JA, Vidal L, et al. Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101). Cancer Chemother Pharmacol. 2011;67(6):1273-1279.
-
(2011)
Cancer Chemother Pharmacol
, vol.67
, Issue.6
, pp. 1273-1279
-
-
Steele, N.L.1
Plumb, J.A.2
Vidal, L.3
-
33
-
-
67650034421
-
A Phase I Study of Oral Belinostat (PXD101) in Patients with Advanced Solid Tumors
-
2007 ASCO Annual Meeting Proceedings (June 20 Supplement)
-
Kelly WK, Yap T, Lee J, et al. A Phase I Study of Oral Belinostat (PXD101) in Patients with Advanced Solid Tumors. 2007 ASCO Annual Meeting Proceedings. Vol 25, No 18S (June 20 Supplement), 2007:14092.
-
(2007)
2007 ASCO Annual Meeting Proceedings
, vol.25
, Issue.18S
, pp. 14092
-
-
Kelly, W.K.1
Yap, T.2
Lee, J.3
-
34
-
-
77955641567
-
Final results of a phase I study of oral belinostat (PXD101) in patients with lymphoma
-
(Suppl; absract 8580)
-
Zain JM, Foss F, Kelly WK, et al. Final results of a phase I study of oral belinostat (PXD101) in patients with lymphoma. J Clin Oncol. 2009;27:15S(Suppl; absract 8580).
-
(2009)
J Clin Oncol
, vol.15S
, pp. 27
-
-
Zain, J.M.1
Foss, F.2
Kelly, W.K.3
-
35
-
-
1642453460
-
Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101
-
Plumb JA, Finn PW, Williams RJ, et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther. 2003;2(8):721-728.
-
(2003)
Mol Cancer Ther
, vol.2
, Issue.8
, pp. 721-728
-
-
Plumb, J.A.1
Finn, P.W.2
Williams, R.J.3
-
36
-
-
84908273523
-
-
National Comprehensive Cancer Network, Available at, Accessed August 12
-
National Comprehensive Cancer Network. Non-Hodgkin’s Lymphomas (Version 3.2014). Available at: http://www.nccn.org/professionals/physi-cian_gls/pdf/nhl.pdf. Accessed August 12, 2014.
-
(2014)
Non-Hodgkin’s Lymphomas (Version 3.2014)
-
-
|